BioSpace News Archive

Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced that members of management are scheduled to participate in four upcoming virtual investor conferences

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive interim data from the third cohort of the Phase 1b open label, dose escalation study of itolizumab in the first-line treatment of acute graft-versus-host disease (aGVHD)

Johnson & Johnson (NYSE: JNJ) will hold a virtual Medical Devices Update for the investment community on Thursday, November 19, 2020, in which leadership will focus on the Company’s differentiated and competitive platforms across digital surgery and provide franchise and innovation highlights across the Johnson & Johnson Medical Devices Companies.

Genesis HealthCare (NYSE:GEN) (Genesis or the Company), one of the nation’s largest providers of post-acute care, today announced that it expects to release its third quarter ended September 30, 2020 results before the market opens on Monday, November 9, 2020.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to potentially overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended on September 30, 2020 and provided an update on recent clinical and corporate developments.

On October 27, the bridging study results on Fexuprazan, developed by the Korean pharmaceutical company, Daewoong Pharmaceutical (Daewoong; CEO Sengho Jeon), was published in the SCI medical journal Alimentary Pharmacology and Therapeutics (AP&T).

The Miami Dade County Board of County Commissioners awarded $3,000,000 in Coronavirus Relief Funds to St. Thomas University’s Center for Pandemic, Disaster and Quarantine Research.

Company Being Sought Out Worldwide for Global Distribution Agreements Based Testing at FDA; CLIA Certified Lab

MYOS RENS Technology Inc. (“MYOS” or the “Company”) (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition that helps build lean muscle, announced today its results fo

Chronic pain has significant impacts on a person’s physical and mental health, often preventing people from enjoying everyday activities.